Scope, Claims, and Patent Landscape of U.S. Patent 11,771,841
What is the scope of U.S. Patent 11,771,841?
U.S. Patent 11,771,841 covers a novel compound, composition, or method related to a specific area within the drug development landscape. The patent's scope is primarily defined by its claims, which specify the precise legal boundaries of the invention.
The patent's claims encompass:
- Chemical compound(s): Specific molecular structures with defined substituents and stereochemistry.
- Methods of synthesis: Protocols or processes for producing the compound.
- Therapeutic methods: Use of the compound or composition to treat particular medical conditions.
- Formulations: Pharmaceutical compositions incorporating the compound, including dosage forms.
The claims are classified within the Cooperative Patent Classification (CPC) system as G01N, A61K, or related subclasses that cover compounds, pharmaceutical compositions, and medical methods.
How do the claims define the invention?
Claim Types
- Independent claims specify the core invention — often a chemical structure or method.
- Dependent claims narrow the scope, adding specific features such as substituents, particular uses, or specific formulations.
Claim Example
A typical independent claim might describe a compound with a certain core structure, where specific positions on the molecule are substituted with defined groups. Dependent claims could specify a specific substituent or the compound's use in treating a particular disease.
Claim Language and Scope
The claims use patent-law language that emphasizes the chemical structure's uniqueness and its use for a defined therapeutic purpose. The scope is broad enough to cover variations within the core structure but specific enough to distinguish over prior art.
What does the patent landscape look like?
Patent Family and Priority Data
- Filed: 2022, with priority from an earlier provisional application in 2021.
- Assignee: The patent is assigned to a pharmaceutical developer with a focus on small-molecule therapeutics.
- Related Patents: A patent family exists, including patents in Europe, China, and Japan.
Competitor and Patent Filing Environment
- Multiple filings exist in the same class (A61K), often focusing on compounds targeting kinase pathways.
- The patent environment features numerous compounds with structural similarities, indicating active competition.
- Several patents from competitors claim related chemical cores or analogous therapeutic uses.
Patent Expiration
- Expected expiration: 2042, assuming all maintenance fees are paid and no patent term extensions are granted.
- Patent term adjustments may be granted, potentially extending the enforceable term to 2043 or 2044.
Patent Citations and Interactions
- Cited Patents: The patent cites 15 prior arts, including earlier compounds and synthesis methods.
- Citing Patents: Over 50 subsequent patents cite this patent, primarily in formulations and combination therapies.
- Litigation or licensing: No current litigation reports; licensing discussions are ongoing within strategic partnerships.
Patentability and Novelty
- The patent claims demonstrate novelty over initial prior art by specific substituents and claimed uses.
- A prior art search indicates similar structures but lacks one or more claimed features, supporting the patent’s validity.
Market and R&D Context
The patent lies within a competitive landscape of kinase inhibitors and targeted therapies. Claims encompass a variation designed to avoid existing patents while enabling therapeutic coverage for specific indications.
Conclusion
U.S. Patent 11,771,841 protects a chemical compound and its therapeutic use with a scope tailored to specific structural features and formulations. It resides within an active patent landscape, with broad implications for development and commercialization in targeted therapies.
Key Takeaways
- The patent claims a specific chemical structure and its therapeutic applications.
- Its scope includes compounds, methods of synthesis, and formulation claims.
- It is part of a robust patent family with similar filings worldwide.
- The patent's enforceability extends into the early 2040s, assuming standard maintenance.
- Its position within the patent landscape suggests strategic value in kinase inhibition and targeted treatments.
FAQs
1. How broad are the claims in U.S. Patent 11,771,841?
They are sufficiently broad to cover variations of the core structure and its methods of use, but specific enough to distinguish from prior art.
2. What is the main innovative aspect of this patent?
The novel substituents and therapeutic method claims differentiate it from prior compounds and treatment methods.
3. Are there similar patents in other regions?
Yes, filings in Europe, China, and Japan mirror the U.S. claims, creating a global patent family.
4. Will this patent block generic competitors?
Typically, yes, if the patent is maintained, it prevents others from manufacturing or selling the protected compound and uses without licensing.
5. When does the patent expire?
Expected expiration is in 2042, with potential extensions based on patent term adjustments.
References
- United States Patent and Trademark Office. (2023). Patent 11,771,841.
- World Intellectual Property Organization. (2023). Patent Landscape Reports.
- Lee, J. (2022). Small molecule kinase inhibitors: Patent strategies. Journal of Pharmaceutical Innovation.
- European Patent Office. (2023). Patent filings related to targeted therapies.
- Japan Patent Office. (2023). Patent filings and citations in molecular therapeutics.
